The Supreme Court of Canada has rejected an attempt by a Toronto-based generic drug maker to prevent brand-name pharmaceutical companies from patenting specific parts of previously patented medicines.
The court ruled unanimously against Apotex Inc. and in favour of France's Sanofi-Synthelabo over a challenge involving the blood-thinner clopidogrel bisulphate. The compound is marketed as Plavix, one of the world's top-selling drugs.
The whole judgement can be read here.
No comments:
Post a Comment